Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report)’s share price traded down 3% during mid-day trading on Wednesday . The company traded as low as $2.53 and last traded at $2.56. 19,574 shares were traded during trading, an increase of 804% from the average session volume of 2,165 shares. The stock had previously closed at $2.64.
Graybug Vision Price Performance
The company has a market cap of $4.16 million, a price-to-earnings ratio of -1.53 and a beta of 1.20. The firm has a fifty day simple moving average of $2.95 and a 200 day simple moving average of $3.72.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
See Also
- Five stocks we like better than Graybug Vision
- Stock Dividend Cuts Happen Are You Ready?
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Where to Find Earnings Call Transcripts
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Canada Bond Market Holiday: How to Invest and Trade
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
